Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Bristol-Myers Squibb Co. (NYSE: BMY).

Full DD Report for BMY

You must become a subscriber to view this report.


Recent News from (NYSE: BMY)

Jounce down 32% premarket on announcement of trial data on lead candidate JTX-2011
Jounce Therapeutics (NASDAQ: JNCE ) slumps  32%  premarket on light volume in response to its announcement that updated safety and efficacy data from its Phase 1/2 ICONIC study evaluating lead candidate JTX-2011 across four solid tumor types will be presented as ASCO in Chicago o...
Source: SeekingAlpha
Date: May, 17 2018 07:12
Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology-Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018
First analysis from Phase 3 CheckMate -227 Part 1b in first-line non-small cell lung cancer, assessing Opdivo plus chemotherapy and Opdivo plus Yervoy versus chemotherapy in patients with PD-L1 <1% Updated data from Phase 3 CheckMate -238 study of Opdivo as adjuvant t...
Source: Business Wire
Date: May, 16 2018 17:07
Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
Eli Lilly Had Good Reason To Spend $1.6B On Armo
Eli Lilly’s ( LLY ) $1.6 billion purchase of Armo Biosciences ( ARMO ) last week has deeper implications than simply making Armo shareholders richer. More important than that, it is a vote of confidence in an approach casting an ever wider net of combining cancer immunotherapies with an...
Source: SeekingAlpha
Date: May, 16 2018 11:24
Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise
In my whole life, I have known no wise people (over a broad subject matter area) who didn't read all the time - none, zero. You’d be amazed at how much Warren reads - and at how much I read. My children laugh at me. They think I’m a book with a couple of legs sticking out. - C...
Source: SeekingAlpha
Date: May, 16 2018 07:09
Don't Buy L Brands - Cramer's Lightning Round (5/15/18)
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, May 15. Bullish Calls Consolidated Edison (ED): It's a buy on weakness. Buy American Electric Power (AEP) too as it's a high quality utility. Clorox (CLX): Buy half now and the other half when i...
Source: SeekingAlpha
Date: May, 16 2018 06:37
Ziopharm, Trump's Drug Pricing Plan And The Future Of Expensive Drug Development
In its quarterly results press release, Ziopharm (ZIOP) indicated that it was suspending its trial of Ad-RTS-hIL-12 plus 20mg dose of veledimex for the treatment of glioblastoma. The news is certainly discouraging from a conventional standpoint, and price action on the announcement corroborate...
Source: SeekingAlpha
Date: May, 15 2018 12:54
Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the UBS 2018 Global Healthcare Conference on Tuesday, May 22, 2018, in New York. Charles Bancroft , executive vice president, Chief Financial Officer and Head of Global Business Operations, will answer questions about the company a...
Source: Business Wire
Date: May, 15 2018 06:59
Ziopharm's Pause On Its Phase 3 Brain Cancer Study Is More Valuable Than You Think
Recently, Ziopharm Oncology (ZIOP) gave an update on its first-quarter 2018 earnings report. It noted that a phase 3 study would be paused for the time being . The biotech is now pointing to its other mid-stage studies as being more prominent than the phase 3 study that was supposed to st...
Source: SeekingAlpha
Date: May, 14 2018 03:55
Trump speech on drug prices light on specifics
Key points from President Trump's speech detailing his plan to lower U.S. drug prices called American Patients First: More news on: Health Care Select Sect SPDR ETF, Vanguard Health Care ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 11 2018 14:25

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1752.0552.7453.4051.968,097,423
2017-11-0761.5861.9162.4361.454,047,238
2017-11-0662.2461.6862.2761.284,222,569
2017-11-0362.0862.2262.2561.7953,327,317
2017-11-0262.1562.2362.8761.734,058,167

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2117,120103,82616.4891Cover
2018-08-2037,449106,30735.2272Short
2018-08-1790,033784,73011.4731Cover
2018-08-16104,930424,88624.6960Cover
2018-08-1543,625158,71127.4871Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BMY.


About Bristol-Myers Squibb Co. (NYSE: BMY)

Logo for Bristol-Myers Squibb Co. (NYSE: BMY)

Not available

 

Contact Information

 

 

Current Management

  • Sandra Leung / Secretary

Current Share Structure

  • Market Cap: $84,767,164,432 - 05/11/2018
  • Issue and Outstanding: 1,634,538,458 - 03/31/2018

 


Recent Filings from (NYSE: BMY)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 23 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: March, 27 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: March, 23 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 22 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NYSE: BMY)

Daily Technical Chart for (NYSE: BMY)


Stay tuned for daily updates and more on (NYSE: BMY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: BMY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BMY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BMY and does not buy, sell, or trade any shares of BMY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/